{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:36:39Z","timestamp":1793338599869,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A lasting imbalance between fatty acid synthesis and consumption leads to non-alcoholic fatty liver disease (NAFLD), coupled with hepatitis and insulin resistance. Yet the details of the underlying mechanisms are not fully understood. Here, we unraveled that the expression of the transcription factor <jats:italic>Zbtb18<\/jats:italic> is markedly decreased in the livers of both patients and murine models of NAFLD. Hepatic <jats:italic>Zbtb18<\/jats:italic> knockout promoted NAFLD features like impaired energy expenditure and fatty acid oxidation (FAO), and induced insulin resistance. Conversely, hepatic <jats:italic>Zbtb18<\/jats:italic> overexpression alleviated hepato-steatosis, insulin resistance, and hyperglycemia in mice fed on a high-fat diet (HFD) or in diabetic mice. Notably, in vitro and in vivo mechanistic studies revealed that <jats:italic>Zbtb18<\/jats:italic> transcriptional activation of Farnesoid X receptor (<jats:italic>FXR<\/jats:italic>) mediated FAO and Clathrin Heavy Chain (<jats:italic>CLTC<\/jats:italic>) protein hinders NLRP3 inflammasome activity. This key mechanism by which hepatocyte\u2019s <jats:italic>Zbtb18<\/jats:italic> expression alleviates NAFLD and consequent liver fibrosis was further verified by <jats:italic>FXR\u2019<\/jats:italic>s deletion and forced expression in mice and cultured mouse primary hepatocytes (MPHs). Moreover, <jats:italic>CLTC<\/jats:italic> deletion significantly abrogated the hepatic <jats:italic>Zbtb18<\/jats:italic> overexpression-driven inhibition of NLRP3 inflammasome activity in macrophages. Altogether, <jats:italic>Zbtb18<\/jats:italic> transcriptionally activates the <jats:italic>FXR<\/jats:italic>-mediated FAO and <jats:italic>CLTC<\/jats:italic> expression, which inhibits NLRP3 inflammasome\u2019s activity alleviating inflammatory stress and insulin resistance, representing an attractive remedy for hepatic steatosis and fibrosis.<\/jats:p>","DOI":"10.1038\/s41392-023-01727-7","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:02:27Z","timestamp":1706054547000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Hepatic Zbtb18 (Zinc Finger and BTB Domain Containing 18) alleviates hepatic steatohepatitis via FXR (Farnesoid X Receptor)"],"prefix":"10.1038","volume":"9","author":[{"given":"Lei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangpeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafeng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-3417","authenticated-orcid":false,"given":"Xiaoqiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"1727_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.celrep.2022.111497","volume":"41","author":"H Tsuneki","year":"2022","unstructured":"Tsuneki, H. et al. Hypothalamic orexin prevents non-alcoholic steatohepatitis and hepatocellular carcinoma in obesity. Cell Rep. 41, 111\u2013497 (2022).","journal-title":"Cell Rep."},{"key":"1727_CR2","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","volume":"3","author":"L Parlati","year":"2021","unstructured":"Parlati, L., R\u00e9gnier, M., Guillou, H. & Postic, C. New targets for NAFLD. JHEP Rep. 3, 100346 (2021).","journal-title":"JHEP Rep."},{"key":"1727_CR3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.jhep.2022.04.002","volume":"76","author":"V Ratziu","year":"2022","unstructured":"Ratziu, V., Francque, S. & Sanyal, A. Breakthroughs in therapies for NASH and remaining challenges. J. Hepatol. 76, 1263\u20131278 (2022).","journal-title":"J. Hepatol."},{"key":"1727_CR4","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","volume":"76","author":"E Scorletti","year":"2022","unstructured":"Scorletti, E. & Carr, R. M. A new perspective on NAFLD: Focusing on lipid droplets. J. Hepatol. 76, 934\u2013945 (2022).","journal-title":"J. Hepatol."},{"key":"1727_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.phrs.2017.01.017","volume":"119","author":"C Mameli","year":"2017","unstructured":"Mameli, C. et al. An update on the assessment and management of metabolic syndrome, a growing medical emergency in paediatric populations. Pharm. Res. 119, 99\u2013117 (2017).","journal-title":"Pharm. Res."},{"key":"1727_CR6","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1001\/jama.2016.6423","volume":"316","author":"P Lozano","year":"2016","unstructured":"Lozano, P. et al. Lipid screening in childhood and adolescence for detection of multifactorial dyslipidemia: evidence report and systematic review for the US preventive services task force. Jama 316, 634\u2013644 (2016).","journal-title":"Jama"},{"key":"1727_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41467-018-05383-2","volume":"9","author":"XY Zhao","year":"2018","unstructured":"Zhao, X. Y. et al. Long noncoding RNA licensing of obesity-linked hepatic lipogenesis and NAFLD pathogenesis. Nat. Commun. 9, 29\u201386 (2018).","journal-title":"Nat. Commun."},{"key":"1727_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcmgh.2020.10.006","volume":"11","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. S100A11 Promotes Liver Steatosis via FOXO1-Mediated Autophagy and Lipogenesis. Cell Mol. Gastroenterol. Hepatol. 11, 697\u2013724 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1727_CR9","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1080\/15548627.2020.1834711","volume":"17","author":"HS Park","year":"2021","unstructured":"Park, H. S. et al. TXNIP\/VDUP1 attenuates steatohepatitis via autophagy and fatty acid oxidation. Autophagy 17, 2549\u20132564 (2021).","journal-title":"Autophagy"},{"key":"1727_CR10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1002\/hep.32324","volume":"76","author":"MP Moore","year":"2022","unstructured":"Moore, M. P. et al. Compromised hepatic mitochondrial fatty acid oxidationand reduced markers of mitochondrial turnover in human NAFLD. Hepatology 76, 1452\u20131465 (2022).","journal-title":"Hepatology"},{"key":"1727_CR11","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224 (2021).","journal-title":"Lancet"},{"key":"1727_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jhep.2013.03.033","volume":"59","author":"C Brenner","year":"2013","unstructured":"Brenner, C., Galluzzi, L., Kepp, O. & Kroemer, G. Decoding cell death signals in liver inflammation. J. Hepatol. 59, 583\u2013594 (2013).","journal-title":"J. Hepatol."},{"key":"1727_CR13","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha, A. R. et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046 (2017).","journal-title":"J. Hepatol."},{"key":"1727_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jhep.2020.07.041","volume":"74","author":"S Gaul","year":"2021","unstructured":"Gaul, S. et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis. J. Hepatol. 74, 156\u2013167 (2021).","journal-title":"J. Hepatol."},{"key":"1727_CR15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molmet.2020.101122","volume":"50","author":"K Pafili","year":"2021","unstructured":"Pafili, K. & Roden, M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol. Metab. 50, 101\u2013122 (2021).","journal-title":"Mol. Metab."},{"key":"1727_CR16","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","volume":"1859","author":"MC Cave","year":"2016","unstructured":"Cave, M. C. et al. Nuclear receptors and nonalcoholic fatty liver disease. Biochim. Biophys. Acta 1859, 1083\u20131099 (2016).","journal-title":"Biochim. Biophys. Acta"},{"key":"1727_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11605-018-3938-z","volume":"23","author":"GS Mazzini","year":"2019","unstructured":"Mazzini, G. S. et al. Concomitant PPAR\u03b1 and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis. J. Gastrointest. Surg. 23, 51\u201357 (2019).","journal-title":"J. Gastrointest. Surg."},{"key":"1727_CR18","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","volume":"33","author":"BL Clifford","year":"2021","unstructured":"Clifford, B. L. et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 33, 1671\u20131684.e1674 (2021).","journal-title":"Cell Metab."},{"key":"1727_CR19","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1016\/j.celrep.2018.07.068","volume":"24","author":"CY Han","year":"2018","unstructured":"Han, C. Y. et al. FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury. Cell Rep. 24, 2985\u20132999 (2018).","journal-title":"Cell Rep."},{"key":"1727_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.metabol.2021.154797","volume":"120","author":"S Huang","year":"2021","unstructured":"Huang, S. et al. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage. Metabolism 120, 154\u2013197 (2021).","journal-title":"Metabolism"},{"key":"1727_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jhep.2021.03.020","volume":"75","author":"C Kremoser","year":"2021","unstructured":"Kremoser, C. FXR agonists for NASH: How are they different and what difference do they make? J. Hepatol. 75, 12\u201315 (2021).","journal-title":"J. Hepatol."},{"key":"1727_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jcmgh.2022.04.011","volume":"14","author":"C Liu","year":"2022","unstructured":"Liu, C. et al. Hepatic SIRT6 Modulates Transcriptional Activities of FXR to Alleviate Acetaminophen-induced Hepatotoxicity. Cell Mol. Gastroenterol. Hepatol. 14, 271\u2013293 (2022).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"1727_CR23","doi-asserted-by":"publisher","first-page":"118477","DOI":"10.1016\/j.lfs.2020.118477","volume":"262","author":"L Chen","year":"2020","unstructured":"Chen, L., Wang, L., Qin, J. & Wei, D. S. CtBP2 interacts with Zbtb18 to promote malignancy of glioblastoma. Life Sci. 262, 118477 (2020).","journal-title":"Life Sci."},{"key":"1727_CR24","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/1541-7786.MCR-16-0494","volume":"15","author":"V Fedele","year":"2017","unstructured":"Fedele, V. et al. Epigenetic Regulation of Zbtb18 Promotes Glioblastoma Progression. Mol. Cancer Res. 15, 998\u20131011 (2017).","journal-title":"Mol. Cancer Res."},{"key":"1727_CR25","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/ni.2022","volume":"12","author":"H Wen","year":"2011","unstructured":"Wen, H. et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12, 408\u2013415 (2011).","journal-title":"Nat. Immunol."},{"key":"1727_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7150\/thno.38198","volume":"10","author":"Z Wan","year":"2020","unstructured":"Wan, Z. et al. Mononuclear phagocyte system blockade improves therapeutic exosome delivery to the myocardium. Theranostics 10, 218\u2013230 (2020).","journal-title":"Theranostics"},{"key":"1727_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.7150\/thno.78878","volume":"13","author":"B Li","year":"2023","unstructured":"Li, B. et al. SIRT6-regulated macrophage efferocytosis epigenetically controls inflammation resolution of diabetic periodontitis. Theranostics 13, 231\u2013249 (2023).","journal-title":"Theranostics"},{"key":"1727_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jhep.2019.09.012","volume":"72","author":"D Caballero-D\u00edaz","year":"2020","unstructured":"Caballero-D\u00edaz, D. et al. Clathrin switches transforming growth factor-\u03b2 role to pro-tumorigenic in liver cancer. J. Hepatol. 72, 125\u2013134 (2020).","journal-title":"J. Hepatol."},{"key":"1727_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1727_CR30","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"1727_CR31","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.3390\/ijms21082986","volume":"21","author":"M Meroni","year":"2020","unstructured":"Meroni, M., Longo, M., Rustichelli, A. & Dongiovanni, P. Nutrition and genetics in NAFLD: The perfect binomium. Int. J. Mol. Sci. 21, 2986 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1727_CR32","doi-asserted-by":"publisher","first-page":"101274","DOI":"10.1016\/j.molmet.2021.101274","volume":"50","author":"A Zeigerer","year":"2021","unstructured":"Zeigerer, A. NAFLD - A rising metabolic disease. Mol. Metab. 50, 101274 (2021).","journal-title":"Mol. Metab."},{"key":"1727_CR33","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1136\/gutjnl-2020-321774","volume":"70","author":"N Sun","year":"2021","unstructured":"Sun, N. et al. Hepatic Kr\u00fcppel-like factor 16 (KLF16) targets PPAR\u03b1 to improve steatohepatitis and IR. Gut 70, 2183\u20132195 (2021).","journal-title":"Gut"},{"key":"1727_CR34","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2012.11.024","volume":"58","author":"H Zhang","year":"2013","unstructured":"Zhang, H. et al. Mouse KLF11 regulates hepatic lipid metabolism. J. Hepatol. 58, 763\u2013770 (2013).","journal-title":"J. Hepatol."},{"key":"1727_CR35","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1172\/JCI66062","volume":"129","author":"A Cui","year":"2019","unstructured":"Cui, A. et al. Dexamethasone-induced Kr\u00fcppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. J. Clin. Invest. 129, 2266\u20132278 (2019).","journal-title":"J. Clin. Invest."},{"key":"1727_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19205-x","volume":"11","author":"BC Wilson","year":"2020","unstructured":"Wilson, B. C. et al. Intellectual disability-associated factor Zbtb11 cooperates with NRF-2\/GABP to control mitochondrial function. Nat. Commun. 11, 5469 (2020).","journal-title":"Nat. Commun."},{"key":"1727_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14824","volume":"8","author":"G Liu","year":"2017","unstructured":"Liu, G. et al. Regulation of hepatic lipogenesis by the zinc finger protein Zbtb20. Nat. Commun. 8, 14824 (2017).","journal-title":"Nat. Commun."},{"key":"1727_CR38","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1210\/me.2014-1164","volume":"28","author":"S Chen","year":"2014","unstructured":"Chen, S. et al. Control of hepatic gluconeogenesis by the promyelocytic leukemia zinc finger protein. Mol. Endocrinol. 28, 1987\u20131998 (2014).","journal-title":"Mol. Endocrinol."},{"key":"1727_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.apsb.2015.01.004","volume":"5","author":"L Ding","year":"2015","unstructured":"Ding, L., Yang, L., Wang, Z. & Huang, W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm. Sin. B 5, 135\u2013144 (2015).","journal-title":"Acta Pharm. Sin. B"},{"key":"1727_CR40","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/hep.32577","volume":"76","author":"W Xu","year":"2022","unstructured":"Xu, W. et al. Hepatocellular cystathionine \u03b3 lyase\/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. Hepatology 76, 1794\u20131810 (2022).","journal-title":"Hepatology"},{"key":"1727_CR41","doi-asserted-by":"publisher","first-page":"135197","DOI":"10.1172\/JCI135197","volume":"131","author":"J Hou","year":"2021","unstructured":"Hou, J. et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis. J. Clin. Invest. 131, 135197 (2021).","journal-title":"J. Clin. Invest."},{"key":"1727_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","volume":"16","author":"K Kazankov","year":"2019","unstructured":"Kazankov, K. et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Nat. Rev. Gastroenterol. Hepatol. 16, 145\u2013159 (2019).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"1727_CR43","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","volume":"68","author":"D Schuppan","year":"2018","unstructured":"Schuppan, D., Surabattula, R. & Wang, X. Y. Determinants of fibrosis progression and regression in NASH. J. Hepatol. 68, 238\u2013250 (2018).","journal-title":"J. Hepatol."},{"key":"1727_CR44","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2741\/4892","volume":"26","author":"S Raza","year":"2021","unstructured":"Raza, S., Rajak, S., Upadhyay, A., Tewari, A. & Anthony Sinha, R. Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front. Biosci. (Landmark Ed.) 26, 206\u2013237 (2021).","journal-title":"Front. Biosci. (Landmark Ed.)"},{"key":"1727_CR45","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-065X.2012.01116.x","volume":"247","author":"SU Lee","year":"2012","unstructured":"Lee, S. U. & Maeda, T. POK\/Zbtb proteins: an emerging family of proteins that regulate lymphoid development and function. Immunol. Rev. 247, 107\u2013119 (2012).","journal-title":"Immunol. Rev."},{"key":"1727_CR46","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/liv.14428","volume":"40","author":"X Li","year":"2020","unstructured":"Li, X. et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int. 40, 1378\u20131394 (2020).","journal-title":"Liver Int."},{"key":"1727_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1074\/jbc.M113.526343","volume":"289","author":"L Shen","year":"2014","unstructured":"Shen, L. et al. Hepatic differentiated embryo-chondrocyte-expressed gene 1 (Dec1) inhibits sterol regulatory element-binding protein-1c (Srebp-1c) expression and alleviates fatty liver phenotype. J. Biol. Chem. 289, 32\u201342 (2014).","journal-title":"J. Biol. Chem."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01727-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01727-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:04:27Z","timestamp":1706054667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-023-01727-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1727"],"URL":"https:\/\/doi.org\/10.1038\/s41392-023-01727-7","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]},"assertion":[{"value":"9 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}